Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion

Diabetes Technology and Therapeutics

Volumn 10, Issue 1, 2008, Pages 1-10

  Wittlin, Steven D ^a   Marcus, Alan O ^b   Weng, C S Wayne ^c   Howard, Campbell P ^c   Schorr, Alan B ^d  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c NOVO NORDISK INC   (United States)

^d St Mary Medical Center Langhorne   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN LISPRO;

ADULT; ANEMIA; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; EVALUATION RESEARCH; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; VOMITING; WEIGHT GAIN;

ADULT; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES;

EID: 38349014282     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2007.0234     Document Type: Article

References (28)

1. Lenhard MJ, Reeves GD: Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med 2001;161:2293-2300.
2. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC: Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 2002;18(Suppl 1):S14-S20.
3. Home PD, Barriocanal L, Lindholm A: Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999;55:199-203.
4. Lindholm A, Jacobsen LV: Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 2001;40:641-659.
5. Trautmann ME: Effect of the insulin analogue [LYS(B28),PRO(B29)] on blood glucose control. Horm Metab Res 1994;26:588-590.
6. Becker RH, Frick AD, Burger F, Scholtz H, Potgieter JH: A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin Endocrinol Diabetes 2005;113:292-297.
7. Radermecker RP, Scheen AJ: Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev 2004;20:178-188.
8. Retnakaran R, Hochman J, DeVries JH, Hanaire-Broutin H, Heine RJ, Melki V, Zinman B: Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 2004;27:2590-2596.
9. Colquitt J, Royle P, Waugh N: Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med 2003;20:863-866.
10. Siebenhofer A, Plank J, Berghold A, Horvath K, Sawicki PT, Beck P, Pieber TR: Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy. Diabetologia 2004;47:1895-1905.
11. Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, Davidson J, Henry R, Huang WC, Reinhardt RR: Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care 2002;25:439-444.
12. Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G: Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care 2003;26:2027-2031.
13. Hoogma RPLM, Schumicki D: Safety of insulin glulisine when given by continuous subcutaneous insulin infusion using an external pump in patients with type 1 diabetes. Horm Metab Res 2006;38:429-433.
14. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R: Insulin pump therapy: a meta-analysis. Diabetes Care 2003;26:1079-1087.
15. Pickup J, Mattock M, Kerry S: Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002;324:705.
16. Pickup J, Keen H: Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002;25:593-598.
17. Wittlin SD: Treating the spectrum of type 2 diabetes: emphasis on insulin pump therapy. Diabetes Educ 2006;32(1 Suppl):39S-46S.
18. Kirk SE, Insulin pump therapy for type 2 diabetes. Curr Diabetes Rep 2003;3:373-377.
19. Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Al Harthi A, Plunkett CD, LaPorte FB, Burke R, Brown MB, Halter JB, Raskin P: A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005;28:1568-1573.
20. Wainstein J, Metzger M, Boaz M, Minuchin O, Cohen Y, Yaffe A, Yerushalmy Y, Raz I, Harman-Boehm I: Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients. Diabet Med 2005;22:1037-1046.
21. Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR: Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 2003;26:2598-2603.
22. Kamoi K, Miyakoshi M, Maruyama R: A quality-of-life assessment of intensive insulin therapy using insulin lispro switched from short-acting insulin and measured by an ITR-QOL questionnaire: a prospective comparison of multiple daily insulin injections and continuous subcutaneous insulin infusion. Diabetes Res Clin Pract 2004;64:19-25.
23. Campbell RK, Sclar DA, Robison LM, Stowers JK, Ferguson JC, Trippe BS, Kayne DM: Impact on clinical status and quality of life of switching from regular insulin to insulin lispro among patients using insulin pumps. Diabetes Educ 1998;24:95-99.
24. Bott U, Ebrahim S, Hirschberger S, Skovlund SE: Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabet Med 2003;20:626-634.
25. Bradley C, Speight J: Patient perceptions of diabetes and diabetes therapy: assessing quality of life. Diabetes Metab Res Rev 2002;18(Suppl 3):S64-S69.
26. Anderson RT, Skovlund SE, Marrero D, Levine DW, Meadows K, Brod M, Balkrishnan R: Development and validation of the insulin treatment satisfaction questionnaire. Clin Ther 2004;26:565-578.
27. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Amended by the 48th General Assembly, Sommerset West, Republic of South Africa, October 1996. JAMA 1997;277:925-926.
28. International Conference of Harmonisation (ICH) Topic E 6, Harmonised Tripartite Guideline for Good Clinical Practice, Step 5, Consolidated Guideline 1 May 1996. http://www.ich.org/LOB/media/MEDIA482.pdf (accessed November 5, 2007).